Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) EBITDA (2016 - 2025)

OptimizeRx (OPRX) has disclosed EBITDA for 16 consecutive years, with $8.6 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 135.8% to $8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.7 million through Dec 2025, up 185.32% year-over-year, with the annual reading at $11.8 million for FY2025, 186.76% up from the prior year.
  • EBITDA hit $8.6 million in Q4 2025 for OptimizeRx, up from $2.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $8.6 million in Q4 2025 to a low of -$10.9 million in Q4 2023.
  • Historically, EBITDA has averaged -$2.0 million across 5 years, with a median of -$2.8 million in 2023.
  • Biggest five-year swings in EBITDA: plummeted 9937.02% in 2022 and later soared 185.06% in 2025.
  • Year by year, EBITDA stood at $621080.0 in 2021, then tumbled by 239.17% to -$864348.0 in 2022, then plummeted by 1161.41% to -$10.9 million in 2023, then surged by 133.33% to $3.6 million in 2024, then soared by 135.8% to $8.6 million in 2025.
  • Business Quant data shows EBITDA for OPRX at $8.6 million in Q4 2025, $2.0 million in Q3 2025, and $3.2 million in Q2 2025.